← SynDRA
EDASALONEXENT
SynDRA canonical compound SYN0038547 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Primary target(s) | NFKB1 | NFKB2 |
| Mechanism of action | NFkB pathway inhibitor |
All known targets
- NFKB1
- NFKB1; NFKB2; RELA; RELB; REL
- NFKB2
Mechanisms of action (all sources)
- NFkB pathway inhibitor
- Inhibitor
Cross-references
Synonyms
- Edasalonexento
- CAT-1004
- CAT1004
- UNII-AF3Z6434KS
- AF3Z6434KS
- Edasalonexent [INN]
- SCHEMBL1823117
- CHEMBL3786673
- JQLBBYLGWHUHRW-KUBAVDMBSA-N
- N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide
- Benzamide, 2-hydroxy-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl)amino)ethyl)-
- N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16, 19-hexaenamidoethyl)-2-hydroxybenzamide
- RefChem:136276
- CAT 1004
- Edasalonexent [USAN]
- Edasalonexent [WHO-DD]
- Edasalonexent (USAN/INN)
- Edasalonexent [USAN:INN]
- orb1707344
- C31H42N2O3
- MFCD30533433
- WHO 10223
- AKOS040741685
- HY-17630
- MS-29122
- CS-0016786
- D12181
- G15961
- T15198
Look up EDASALONEXENT in the interactive SynDRA portal →